In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it
When GLP- 1 receptors are activated, adenosine triphosphate (ATP) is converted to cyclic adenosine monophosphate (cAMP)
It cannot establish both molecular identities, the declared ratio, net quantity, uniformity, aggregation, stability or microbiological quality
This effect was fully suppressed by the microglial inhibitor minocycline and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, underscoring the essential role of microglial activation and the p38 MAPK pathway [72]
Submit the completed form according to your insurance provider's guidelines